-0.31%
19.08%
22.59%
21.49%
-10.55%
-41.95%
38.62%
AI Spotlight on DIM
Company Description
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide.The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products.It also provides cell cultivation, fermentation, filtration, purification, and fluid management services; single-use and reusable hollow-fiber membrane devices, as well as presterilized assemblies for cell and gene therapy applications; and cell harvesting and various other solutions for intensified bioprocesses.
In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production.It serves manufacturers of pharmaceuticals, foods, and chemicals, as well as research and development laboratories.The company was founded in 1870 and is headquartered in Aubagne, France.
Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Market Data
| Last Price | 224.7 |
| Change Percentage | -0.31% |
| Open | 225.6 |
| Previous Close | 225.4 |
| Market Cap ( Millions) | 21867 |
| Volume | 20744 |
| Year High | 281 |
| Year Low | 139.1 |
| M A 50 | 190.81 |
| M A 200 | 183.44 |
Financial Ratios
| FCF Yield | 1.80% |
| Dividend Yield | 0.00% |
| ROE | 4.74% |
| Debt / Equity | 72.57% |
| Net Debt / EBIDTA | 325.41% |
| Price To Book | 5.65 |
| Price Earnings Ratio | 130.48 |
| Price To FCF | 55.65 |
| Price To sales | 7.99 |
| EV / EBITDA | 33.54 |
News
- 07:04 - Sartorius Stedim Biotech SA (SDMHF) Q4 2024 Earnings Call Highlights: Navigating Growth Amid ...
- Nov -22 - Sartorius Stedim Biotech opens bioprocess centre in the US
- Oct -18 - Sartorius Stedim Biotech SA (SDMHF) Q3 2024 Earnings Call Highlights: Navigating Market ...
- Oct -19 - SARTORIUS (SARTF) Q3 Earnings Lag Estimates
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Biopharmaceuticals
Expected Growth : 10 %
What the company do ?
Biopharmaceuticals from Sartorius Stedim Biotech S.A. refers to the development and manufacturing of biologic medications, vaccines, and diagnostics using living cells or organisms.
Why we expect these perspectives ?
Sartorius Stedim Biotech S.A.'s biopharmaceuticals segment growth is driven by increasing demand for biologics, rising adoption of single-use technologies, and growing outsourcing trends in the biopharmaceutical industry. Additionally, the company's strong product portfolio, strategic acquisitions, and expanding presence in emerging markets contribute to its 10% growth.
Sartorius Stedim Biotech S.A. Products
| Product Range | What is it ? |
|---|---|
| Bioreactors | Sartorius Stedim Biotech's bioreactors are designed for cell culture and fermentation applications, offering scalable and flexible solutions for biopharmaceutical development and production. |
| Fermenters | Sartorius Stedim Biotech's fermenters are designed for microbial fermentation, offering high-performance solutions for bioproduct development and production. |
| Downstream Processing Equipment | Sartorius Stedim Biotech's downstream processing equipment is designed for the purification and separation of bioproducts, offering scalable and flexible solutions for biopharmaceutical development and production. |
| Single-Use Systems | Sartorius Stedim Biotech's single-use systems are designed for biopharmaceutical development and production, offering flexible and scalable solutions for cell culture, fermentation, and downstream processing. |
| Analytics and Testing | Sartorius Stedim Biotech's analytics and testing solutions are designed for the development and production of biopharmaceuticals, offering a range of analytical instruments and services. |
| Process Development Services | Sartorius Stedim Biotech's process development services are designed to support biopharmaceutical development and production, offering expertise in process development, optimization, and scale-up. |
Sartorius Stedim Biotech S.A.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Sartorius Stedim Biotech S.A. is medium due to the presence of alternative products and services in the biotechnology industry.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Sartorius Stedim Biotech S.A.'s products and services, which limits the ability of customers to negotiate prices.
Bargaining Power Of Suppliers
The bargaining power of suppliers is medium due to the presence of multiple suppliers in the market, but Sartorius Stedim Biotech S.A.'s large scale of operations gives it some negotiating power.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the biotechnology industry, including the need for significant investments in research and development.
Intensity Of Rivalry
The intensity of rivalry is high due to the presence of several established players in the biotechnology industry, leading to a competitive market environment.
Strength
Capital Structure
| Value | |
|---|---|
| Debt Weight | 57.64% |
| Debt Cost | 4.83% |
| Equity Weight | 42.36% |
| Equity Cost | 7.14% |
| WACC | 5.81% |
| Leverage | 136.05% |
Sartorius Stedim Biotech S.A. : Quality Control
Sartorius Stedim Biotech S.A. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TDVOX.ST | Tobii Dynavox AB (Publ) develops and sells assistive technology products for communication in Sweden and internationally. The company provides technology and solutions for augmentative and alternative communication for people with … |
| EL.PA | EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in North America, Europe, Latin America, Asia, Oceania, and Africa. It operates in five segments: Wholesale, Retail, Lenses … |
| COLO-B.CO | Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice … |
| AFX.DE | Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, the United States, Asia, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. … |
| STMN.SW | Straumann Holding AG provides tooth replacement and orthodontic solutions worldwide. It researches, develops, manufactures, and supplies dental implants, instruments, CADCAM prosthetics, orthodontic aligners, biomaterials, and digital solutions for use in … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
EssilorLuxottica
A-Score
1-Year Total Return ->
🥈
Coloplast
A-Score
1-Year Total Return ->
🥉
Straumann
A-Score
1-Year Total Return ->
4
Carl Zeiss Meditec
A-Score
1-Year Total Return ->
5
Tobii Dynavox
A-Score
1-Year Total Return ->
6
